Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1

Interventions

Cyclophosphamide 23Temozolomide 14Filgrastim 13Irinotecan 12Melphalan 11Etoposide 10Carboplatin 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8X-Rays 7Topotecan 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Busulfan 7fludarabine 6Thiotepa 6Phantoms, Imaging 6fludarabine phosphate 5Radiotherapy 5Biopsy 5Antilymphocyte Serum 5Oxaliplatin 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methylprednisolone 4Ifosfamide 4Cisplatin 4palbociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × MAGEA3 protein, human × Sarcoma × Clear all
NCT00944580 2017-11-24

A Vaccine Study for High Risk Cancers

Penn State University

Phase 1 Withdrawn
CNSSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡